Evidence map›Paper›PMID 33141853›Full record

Observational studyPLoS neglected tropical diseases2020

Serious limitations of the current strategy to control Soil-Transmitted Helminths and added value of Ivermectin/Albendazole mass administration: A population-based observational study in Cameroon.

Linda Djune-Yemeli, Hugues C Nana-Djeunga, Cédric G Lenou-Nanga, Cyrille Donfo-Azafack, André Domche, Floribert Fossuo-Thotchum, Yannick Niamsi-Emalio, Francine Ntoumi, Joseph Kamgno

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Linda Djune-YemeliCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Hugues C Nana-DjeungaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.ORCID 0000-0002-4496-6048
Cédric G Lenou-NangaCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Cyrille Donfo-AzafackCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
André DomcheCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Floribert Fossuo-ThotchumCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Yannick Niamsi-EmalioCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.ORCID 0000-0002-5766-6255
Francine NtoumiFondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo.
Joseph KamgnoCentre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaoundé, Cameroon.
Université de Yaoundé I · CMFondation Congolaise Pour La Recherche Médicale · CG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSoil-transmitted helminth (STH) infections remain a public health concern in sub-Saharan Africa. School-based mass drug administration (MDA) using the anthelminthic drug Mebendazole/Albendazole have succeeded in controlling morbidity associated to these diseases but failed to interrupt their transmission. In areas were filarial diseases are co-endemic, another anthelminthic drug (Ivermectin) is distributed to almost the entire population, following the community-directed treatment with ivermectin (CDTI) strategy. Since Ivermectin is a broad spectrum anthelmintic known to be effective against STH, we conducted cross-sectional surveys in two health districts with very contrasting histories of Ivermectin/Albendazole-based PC in order to investigate whether CDTI might have contributed in STH transmission interruption. METHODOLOGY: Cross-sectional surveys were conducted in two health districts with similar socio-environmental patterns but with very contrasting CDTI histories (Akonolinga health district where CDTI was yet to be implemented vs. Yabassi health district where CDTI has been ongoing for two decades). Stool samples were collected from all volunteers aged >2 years old and analyzed using the Kato-Katz technique. Infections by different STH species were compared between Akonolinga and Yabassi health districts to decipher the impact of Ivermectin/Albendazole-based MDA on STH transmission. PRINCIPAL

findingsA total of 610 and 584 participants aged 2-90 years old were enrolled in Akonolinga and Yabassi health districts, respectively. Two STH species (Ascaris lumbricoides and Trichuris trichiura) were found, with prevalence significantly higher in Akonolinga health district (43.3%; 95% CI: 38.1-46.6) compared to Yabassi health district (2.5%; 95% CI: 1.1-5.1) (chi-square: 90.8; df: 1; p < 0.001). CONCLUSION/SIGNIFICANCE: These findings (i) suggest that Mebendazole- or Albendazole-based MDA alone distributed only to at-risk populations might not be enough to eliminate STH, (ii) support the collateral impact of Ivermectin/Albendazole MDA on A. lumbricoides and T. trichiura infections, and (iii) suggest that Ivermectin/Albendazole-based PC could accelerate STH transmission interruption.

Indexed as

AdolescentAdultAgedAged, 80 and overAlbendazoleAncylostomatoideaAnimalsAnthelminticsAntiparasitic AgentsAscariasisAscaris lumbricoidesCameroonChildChild, PreschoolCross-Sectional StudiesFecesAlbendazoleAnthelminticsAntiparasitic AgentsIvermectinMebendazoleSoil

Identifiers

PMID33141853
PMCPMC7665818
OpenAlexW3097475781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.